Market capitalization | $160.00m |
Enterprise Value | $301.40m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 814.59 |
P/S ratio (TTM) P/S ratio | 432.43 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -99.71% |
Revenue (TTM) Revenue | $370.00k |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
6 Analysts have issued a Seres Therapeutics Inc forecast:
6 Analysts have issued a Seres Therapeutics Inc forecast:
Dec '23 |
+/-
%
|
||
Net Profit | -114 -114 |
55%
55%
|
|
Depreciation and Amortization | 15 15 |
28%
28%
|
|
Stock Compensation | 34 34 |
34%
34%
|
|
Operating Cash Flow | -117 -117 |
49%
49%
|
|
Investments | 7.98 7.98 |
19%
19%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -125 -125 |
47%
47%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Eric Shaff |
Employees | 233 |
Founded | 2010 |
Website | www.serestherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.